| 摘要 |
1. The method of detecting the presence of glucagon antagonists - Characterized in that: It consists of the following stages: (a) a compound is exposed, in the presence of glucagon antagonists, to the recombined glucagon receptor connected with the response pathway in the conditions and for the period of time, which allow the compound to bind to the receptor and generate a response of the pathway. The recombined glucagon receptor comprises a sequence of amino acids, selected from the group, which includes: sequence of amino acids with Sequence Identifier No. 15 from Met, amino acid No. 1, to Thr, amino acid No. 485; sequence of amino acids with Sequence Identifier No. 15 from Gin, amino acid No. 28, to Tyr, amino acid No. 142; sequence of amino acids with Sequence Identifier No. 25 from Met, amino acid No. 1, to Phe, amino acid No. 477; or their allelic variations and modifications with the substitution, addition or deletion of amino acids and is coded by a DNA molecule, which covers a sequence of nucleotides selected from the following group: nucleotide sequence with Sequence Identifier No. 14, from nucleotide 145 to nucleotide 1599; nucleotide sequence with Sequence Identifier No. 14, from nucleotide 226 to nucleotide 570, and nucleotide sequence with Sequence Identifier No. 24, from nucleotide 53 to nucleotide 1486, or their allelic variations, degenerated sequences or [sequences] able to hybridise with the above-mentioned DNA sequence in the conditions of high or low sharpness, followed by (b) the examination of the decrease in the activation of the response pathway, caused by binding the compound with glucagon receptor in relation to response pathway activation by the glucagon agonist alone, which leads to detection of glucagon antagonist presence. |
